NASDAQ:INBX
Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc.'s revenue grew 550.0% in fiscal 2025 to $1.3M while operating margin rose to −10386.5%, its highest in 3 years. Free cash flow was −$129.8M, −9986.5% of revenue, and the diluted share count rose 3.4%.Summary generated from Inhibrx Biosciences, Inc.'s SEC filings. Latest annual report filed Mar 19, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$1.3M
Revenue growth+550.0%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−10386.5%
Net margin−10773.5%
ROICn/a
Return on equity−197.8%
Debt / equity12.58
Free cash flow−$129.8M
FCF margin−9986.5%
Share count change+3.4%
Financials
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 2 | 0 | 1 |
| Operating income | −219 | −331 | −135 |
| Net income | −241 | 1,688 | −140 |
| Free cash flow | −198 | −197 | −130 |
Recent filings
- 4Insider transaction report
Sep 28, 2026 - 8-KRegulation FD disclosure
Sep 28, 2026 - 4Insider transaction report
Sep 23, 2026 - 8-KRegulation FD disclosure
Sep 8, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KEntry into a material agreement
Jul 16, 2026 - 8-KRegulation FD disclosure
Jun 15, 2026